Legal Tussle Threatens to Embroil ADCS
The University of California, San Diego, is suing the University of Southern California and Alzheimer scientists.
6397 RESULTS
Sort By:
The University of California, San Diego, is suing the University of Southern California and Alzheimer scientists.
Mutant SOD1 prevents immature lysosomes from traveling along the axon and from maturing, leaving the cell with no means to clear broken-down mitochondria.
The foundation recognizes the two researchers for their work on the molecular underpinnings Alzheimer’s disease.
Clever optical corrections reveal microglia and neurons through the intact mouse cranium.
Findings suggest a severe blow to the head twists the protein's backbone, which may lead to neurofibrillary tangles.
A year after social media campaign, what happened with the money?
Massive Mouse Study Bolsters Rationale for Combination Therapy TREM2 Tidbits at AAIC: Genetics, Clinical Data New Data on Autosomal-Dominant Alzheimer’s Point to Early Fissures in the Brain’s Microarchitecture Aducanumab, Solanezumab, Gantenerumab Data Li
Enzyme converts pro-drug to estradiol in the cortex and hippocampus.
Probing this this Alzheimer’s risk factor, scientists find a novel variant, but no consensus yet on how this cell surface receptor increases risk for disease.
A sense of shared purpose energized a day of exchange between families with autosomal-dominant AD and researchers engaged in the Dominantly Inherited Alzheimer Network.
Bypass budget promises tide may be turning on an underfunded disease as families with autosomal-dominant Alzheimer’s discuss how to navigate their daily challenges.
Regulatory and pharma scientists fielded pleas from families with autosomal-dominant Alzheimer’s disease just prior to the AAIC conference.
100 DIAN Family Members Gather for Their First International Meeting At DIAN Family Meeting, Funding News Caps Talk of Inadequate Services Families Challenge DIAN Scientists to Do Even More, Faster Throughout the five days of the 2015 Alzheimer's Ass
Tiny injuries to capillaries in white matter, and to cells in gray matter, have come to be the focus of new imaging measures being explored in early presymptomatic AD.
At AAIC, new data on three anti-Aβ antibodies reinforced a sense of hope that Aβ immunotherapy may yet work out. Challenges with each antibody notwithstanding, all four leading candidates, including crenezumab, are now in Phase 3.